Apollomics
APLM
12 hedge funds and large institutions have $8.54M invested in Apollomics in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
20% more funds holding
Funds holding: 10 → 12 (+2)
1.89% less ownership
Funds ownership: 1.99% → 0.1% (-1.9%)
87% less capital invested
Capital invested by funds: $67.8M → $8.54M (-$59.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$67.3K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$53.9K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$39.5K |
| 4 |
B
Bensler
Bellevue,
Washington
|
+$30.9K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$24.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$11.6M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$52.2K |
| 3 |
Barclays
London,
United Kingdom
|
-$3.39K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1K |
APLM Hedge Fund Activity: Q4 2023 in Review
12 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Apollomics (APLM) for Q4 2023, worth a combined $8.54M — down 87% from $67.8M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new APLM positions and 3 closed out — a net gain of 2 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $67.3K. The largest seller was OrbiMed, cutting an estimated $11.6M.
- 12 institutional investors held Apollomics (APLM) as of Q4 2023, up from 10 in Q3 2023.
- Funds reported $8.54M of Apollomics stock for Q4 2023, down 87% quarter-over-quarter.
- 5 funds opened new Apollomics positions in Q4 2023 and 3 closed out, a net change of +2 holders.
- The largest Apollomics buyer in Q4 2023 was Citadel Advisors, an estimated $67.3K added.
- The largest Apollomics seller in Q4 2023 was OrbiMed, an estimated $11.6M sold.
Based on aggregated 13F filings for Q4 2023.